The United Kingdom and the United States have reached a significant commercial pact that will preserve no import taxes on British pharmaceutical shipments entering the American market.
The Terms of the Pact
As part of the deal, the UK has committed to boost expenditure on pharmaceuticals through the public health system. This move secures that tariffs on these vital goods will be held at nothing for a timeframe of the next three years.
This development is in response to earlier threats to dramatically increase import taxes on branded pharmaceutical products, with increases discussed as high as 100%.
"This agreement with the United Kingdom bolsters the international landscape for new treatments and introduces long-overdue fairness to U.S.–U.K. drug exports," a statement said.
Trade Significance
Drugs are one of the the United Kingdom's biggest goods shipped to the America, which is clearly the biggest destination for large UK drugmakers.
Export figures indicate that in the 12 months leading up to September, the UK sold medicines totaling £11.1bn to the US. This amount represented nearly one-fifth of British export trade in that period.
"This guarantee secures employment, stimulates capital expenditure and facilitates the UK to become a global hub for medical research," the Business and Trade Secretary commented.
Detailed UK Commitments
The pact includes several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to double total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must return to the NHS to prevent overspending will be limited at 15%. Last year, rebates were more than 20%.
Broader Context
This agreement takes place against a long-running row between the sector and the ministers over spending levels and regulatory access.
The disagreement were intensified by assertions that American customers were paying a premium for the same drugs than consumers in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or abandoned, while substantial investments have been directed toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on treatments, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.
